Wouldn’t it be great if HLS listened to Buffett - HLS being a serial offender of normalisation adjustments that fool nobody:
”Despite our recent additions to marketable equities, the most valuable grove in Berkshire’s forest remains the many dozens of non-insurance businesses that Berkshire controls (usually with 100% ownership and never with less than 80%). Those subsidiaries earned $16.8 billion last year. When we say “earned,” moreover, we are describing what remains after all income taxes, interest payments, managerial compensation (whether cash or stock-based), restructuring expenses, depreciation, amortization and home-office overhead.That brand of earnings is a far cry from that frequently touted by Wall Street bankers and corporate CEOs. Too often, their presentations feature “adjusted EBITDA,” a measure that redefines “earnings” to exclude a variety of all-too-real costs.
For example, managements sometimes assert that their company’s stock-based compensation shouldn’t be counted as an expense. (What else could it be – a gift from shareholders?) And restructuring expenses? Well, maybe last year’s exact rearrangement won’t recur. But restructurings of one sort or another are common in business – Berkshire has gone down that road dozens of times, and our shareholders have always borne the costs of doing so.
Abraham Lincoln once posed the question: “If you call a dog’s tail a leg, how many legs does it have?” and then answered his own query: “Four, because calling a tail a leg doesn’t make it one.” Abe would have felt lonely on Wall Street.”
- Forums
- ASX - By Stock
- HLS
- Underlying earnings adjustments
Underlying earnings adjustments
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HLS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.35 |
Change
0.035(2.66%) |
Mkt cap ! $1.212B |
Open | High | Low | Value | Volume |
$1.35 | $1.36 | $1.33 | $1.778M | 1.321M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6637 | $1.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.35 | 6178 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 39836 | 1.650 |
4 | 64577 | 1.645 |
1 | 17980 | 1.640 |
1 | 32000 | 1.635 |
1 | 32130 | 1.625 |
Price($) | Vol. | No. |
---|---|---|
1.665 | 4665 | 2 |
1.670 | 17980 | 1 |
1.675 | 48784 | 2 |
1.680 | 17298 | 3 |
1.690 | 8284 | 3 |
Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
Featured News
HLS (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online